| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | RARB; HAP; NR1B2; Retinoic acid receptor beta; RAR-beta; HBV-activated protein; Nuclear receptor subfamily 1 group B member 2; RAR-epsilon |
| Entrez GeneID | 5915 |
| WB Predicted band size | Calculated MW: 50 kDa; Observed MW: 55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Retinoic Acid Receptor beta |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于Retinoic Acid Receptor beta(RARβ)抗体的文献参考，包含文献名称、作者及摘要内容概括：
1. **文献名称**：*"Retinoic Acid Receptor Beta Expression is Epigenetically Regulated in Human Breast Cancer"*
**作者**：Sirchia, S.M. et al.
**摘要**：研究揭示了RARβ在乳腺癌中的表达缺失与启动子区域异常高甲基化相关，通过Western blot和免疫组化实验(使用特异性RARβ抗体)证实了RARβ蛋白表达水平与肿瘤恶性程度呈负相关。
2. **文献名称**：*"Loss of Retinoic Acid Receptor Beta in Lung Cancer: A Potential Prognostic Marker"*
**作者**：Volante, M. et al.
**摘要**：该文献利用抗RARβ抗体进行免疫组织化学分析，发现非小细胞肺癌组织中RARβ表达显著降低，且低表达与患者生存率下降相关，提示其作为预后标志物的潜力。
3. **文献名称**：*"RARβ-Mediated Signaling Pathways in Neural Differentiation"*
**作者**：Janesick, A. et al.
**摘要**：通过体外细胞模型和小鼠胚胎实验(使用RARβ抗体检测蛋白定位)，研究证实RARβ在视黄酸诱导的神经分化中起关键作用，调控下游靶基因如SOX2的表达。
4. **文献名称**：*"Antibody-Based Detection of RARβ Isoforms in Embryonic Stem Cells"*
**作者**：Chithalen, J.V. et al.
**摘要**：开发了一种特异性识别RARβ不同亚型的单克隆抗体，并通过流式细胞术和免疫荧光验证其在胚胎干细胞中的表达模式，为研究RARβ异构体功能提供工具。
(注：以上文献为示例性概括，实际引用时请核对原文准确性。)
The retinoic acid receptor beta (RARβ) is a nuclear hormone receptor that plays a critical role in mediating the biological effects of retinoic acid (RA), a derivative of vitamin A. As a ligand-activated transcription factor, RARβ regulates gene expression by binding to retinoic acid response elements (RAREs) in target DNA sequences, often in partnership with retinoid X receptors (RXRs). It is involved in diverse cellular processes, including differentiation, proliferation, apoptosis, and embryonic development. Dysregulation of RARβ has been implicated in various pathologies, particularly cancer, where its downregulation or loss is associated with tumor progression, metastasis, and resistance to retinoid-based therapies.
RARβ antibodies are essential tools for studying the expression, localization, and function of this receptor in both normal and diseased tissues. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to detect RARβ protein levels in cellular or tissue samples. Specific RARβ antibodies can distinguish between isoforms (e.g., RARβ1. RARβ2. RARβ4) and help elucidate their distinct roles in cellular signaling. In cancer research, RARβ antibodies are employed to assess receptor status as a potential biomarker for prognosis or therapeutic response. Additionally, they aid in validating RARβ-targeted drug candidates and understanding mechanisms of retinoid resistance. Validation of antibody specificity through knockdown/knockout models or peptide blocking is critical to ensure reliable experimental outcomes.
×
